Biotech News
Immuneering and Regeneron Partner to Evaluate IMM-1-104 in RAS-Mutant Lung Cancer
Immuneering Corporation (Nasdaq: IMRX) has announced a clinical supply agreement with Regeneron Pharmaceuticals to evaluate the combination of Libtayo (cemiplimab), Regeneron’s anti-PD-1 therapy, with Immuneering’s lead candidate, IMM-1-104, in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC).
10 February 2025
Stay ahead of trends and best practices
